Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition

Journal of Neuroscience

Volumn 28, Issue 32, 2008, Pages 8040-8052

  Costa, Cinzia ^a,b   Belcastro, Vincenzo ^a,b   Tozzi, Alessandro ^a,b   Di Filippo, Massimiliano ^a,b   Tantucci, Michela ^a,b   Siliquini, Sabrina ^a,b   Autuori, Alessia ^a,b   Picconi, Barbara ^a,b   Spillantini, Maria Grazia ^c   Fedele, Ernesto ^d   Pittaluga, Anna ^d   Raiteri, Maurizio ^d   Calabresi, Paolo ^a,b,e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Antiepileptic drugs; Dopamine; GABA; Parkinson's disease; Rotenone; Striatum

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTICONVULSIVE AGENT; ASPARTIC ACID; BICUCULLINE; CARBAMAZEPINE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EXCITATORY AMINO ACID; LAMOTRIGINE; MEMANTINE; OXIDOPAMINE; PICROTOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TETRODOTOXIN; TOPIRAMATE; TRITIUM; VALPROIC ACID; VANOXERINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN ELECTROPHYSIOLOGY; BRAIN MITOCHONDRION; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG TARGETING; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATCH CLAMP; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RAT; RESPIRATORY CHAIN; ACTION POTENTIAL; ANIMAL; CORPUS STRIATUM; DOSE RESPONSE; DRUG ANTAGONISM; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; IN VITRO STUDY; INTRACELLULAR SPACE; MALE; METABOLISM; MITOCHONDRION; MOUSE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SYNAPTOSOME; TRANSGENIC MOUSE; WISTAR RAT;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; INTRACELLULAR SPACE; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; ROTENONE; SYNAPTOSOMES;

EID: 51149083921     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1947-08.2008     Document Type: Article

References (53)

1. An JJ, Bae MH, Cho SR, Lee SH, Choi SH, Lee BH, Shin HS, Kim YN, Park KW, Borrelli E, Baik JH (2004) Altered GABAergic neurotransmission in mice lacking dopamine D2 receptors. Mol Cell Neurosci 25:732-741.
2. 2 elevation, not ATP depletion. J Neurosci 25:10029-10040.
3. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
4. Bonsi P, Calabresi P, De Persis C, Papa M, Centonze D, Bernardi G, Pisani A (2004) Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. Exp Neurol 185:169-181.
5. Bozzi Y, Borrelli E (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci 29:167-174.
6. Braak H, Braak E (2000) Pathoanatomy of Parkinson's disease. J Neurol 247 [Suppl 2]:II3-II10.
7. Bracci E, Centonze D, Bernardi G, Calabresi P (2002) Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol 87:2190-2194.
8. Burn DJ, Lees AJ (2002) Progressive supranuclear palsy: where are we now? Lancet Neurol 1:359-369.
9. Calabresi P, Ascone CM, Centonze D, Pisani A, Sancesario G, D'Angelo V, Bernardi G (1997) Opposite membrane potential changes induced by glucose deprivation in striatal spiny neurons and in large aspiny interneurons. J Neurosci 17:1940-1949.
10. Calabresi P, Marfia GA, Centonze D, Pisani A, Bernardi G (1999) Sodium influx plays a major role in the membrane depolarization induced by oxygen and glucose deprivation in rat striatal spiny neurons. Stroke 30:171-179.
11. Calabresi P, Centonze D, Bernardi G (2000) Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology 55:1249-1255.
12. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21:5110-5120.
13. Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G (2003) Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol 53:693-702.
14. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211-219.
15. Centonze D, Marfia GA, Pisani A, Picconi B, Giacomini P, Bernardi G, Calabresi P (2001) Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. Prog Neurobiol 63:687-696.
16. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB, Pisani A, Tognazzi N, Bernardi G, Moratalla R, Borrelli E, Calabresi P (2003) Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 23:6245-6254.
17. Centonze D, Gubellini P, Usiello A, Rossi S, Tscherter A, Bracci E, Erbs E, Tognazzi N, Bernardi G, Pisani A, Calabresi P, Borrelli E (2004) Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience 129:157-166.
18. Centonze D, Prosperetti C, Barone I, Rossi S, Picconi B, Tscherter A, De Chiara V, Bernardi G, Calabresi P (2006) NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp Neurol 202:470-479.
19. Costa C, Leone G, Saulle E, Pisani F, Bernardi G, Calabresi P (2004) Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke 35:596-600.
20. Costa C, Martella G, Picconi B, Prosperetti C, Pisani A, Di Filippo M, Pisani F, Bernardi G, Calabresi P (2006) Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37:1319-1326.
21. Daniel SE, de Bruin VM, Lees AJ (1995) The clinical and pathological spectrum of Steele-Richardson-Olszewski sindrome (progressive supranuclear palsy): a reappraisal. Brain 118:759-770.
22. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822.
23. Di Filippo M, Picconi B, Costa C, Bagetta V, Tantucci M, Parnetti L, Calabresi P (2006) Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur J Pharmacol 545:65-72.
24. Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753:157-162.
25. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF (2004) Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187:418-429.
26. Greene JG, Greenamyre JT (1996) Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48:613-634.
27. Harsing LG Jr, Zigmond MJ (1997) Influence of dopamine on GABA-release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 77:419-429.
28. Höglinger GU, Féger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84:491-502.
29. Höglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95:930-939.
30. Höglinger GU, Oertel WH, Hirsch EC (2006) The rotenone model of parkinsonism: the five years inspection. J Neural Transm 70:269-272.
31. +-evoked serotonin release. Br J Pharmacol 133:557-567.
32. Luetjens CM, Bui NT, Sengpiel B, Munstermann G, Poppe M, Krohn AJ, Bauerbach E, Krieglstein J, Prehn JH (2000) Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J Neurosci 200:5715-5723.
33. Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4:18-61.
34. Morselli PL, Baruzzi A, Gerna M, Bossi L, Porta M (1977) Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. Br J Clin Pharmacol 4:535-540.
35. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S (2001) Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 134:507-520.
36. Okada M, Kiryu K, Kawata Y, Mizuno K, Wada K, Tasaki H, Kaneko S (1997) Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 321:181-188.
37. +, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 124:1277-1285.
38. Okada M, Zhu G, Yoshida S, Kanai K, Hirose S, Kaneko S (2002) Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci 72:465-473.
39. Pearce JM (2007) Progressive supranuclear palsy (Steele-Richardson- Olszewski syndrome): a short historical review. Neurologist 13:302-304.
40. Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
41. Raiteri M, Angelini F, Levi G (1974) A simple apparatus for studying the release of neurotransmitters from synaptosomes. Eur J Pharmacol 25:411-414.
42. Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564.
43. Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M, Bernardi G, Calabresi P (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 25:9-20.
44. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
45. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
46. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003a) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23:10756-10764.
47. Sherer TB, Kim JH, Betarbet R, Greenamyre JT (2003b) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179:9-16.
48. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100:1469-1479.
49. Sims NR, Pulsinelli WA (1987) Altered mitochondrial respiration in selectively vulnerable brain subregions following transient forebrain ischemia in the rat. J Neurochem 49:1367-1374.
50. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208.
51. Tofaris GK, Garcia Reitböck P, Humby T, Lambourne SL, O'Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26:3942-3950.
52. Tozzi A, Costa C, Di Filippo M, Tantucci M, Siliquini S, Belcastro V, Parnetti L, Picconi B, Calabresi P (2007) Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. Exp Neurol 207:218-226.
53. Yoshida S, Okada M, Zhu G, Kaneko S (2007) Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 52:1538-1546.